Turkey: Pharmaceutical Regulations Under Turkish Law

Last Updated: 28 August 2012
Article by Dr. E. Seyfi Moroğlu, LL.M.

Pharmaceutical Regulations under Turkish Law

This article is designed to provide a brief introduction to the requirements for licensing, importing, and introducing pharmaceutical products to the Turkish market. Some key issues to keep in mind are the documents necessary for registration and licensing, the timeline for accomplishing the regulatory work, the terms of data exclusivity that might apply to the products, and pricing regulations and schemes which are also relevant to companies wishing to manufacture or distribute their pharmaceuticals products in Turkey.

For the specific purpose of this article, references are made to Licensing Regulation on Human Medicinal Products ("Licensing Regulation").

Licensing

Pursuant to Article 5 of the Licensing Regulation, pharmaceutical products cannot be launched on the market before obtaining a license to be granted by the Ministry of Health. In order to obtain a license, real persons or legal entities resident in Turkey shall file an application to the Ministry of Health by submitting the documents listed under the Licensing Regulation, published in the Official Gazette dated January 19, 2005 and numbered 25705.

The application documents include, without limitation, (i) description of control methods used by the manufacturer; (ii) toxicological and pharmacological tests and clinical trials; and (iii) where a pharmaceutical product is manufactured under a license (granted by a third party owner of intellectual property) or will be imported, a certificate (and a Turkish translation thereof) issued by the licensor or the supplier demonstrating that the manufacturer/importer is the sole representative which is authorized to manufacture and/or sell the product in Turkey, or if any, a certificate illustrating that a real person or legal entity other than the sole authorized representative in Turkey has also been authorized for co-marketing, and the written consents of the real persons or legal entities which will be engaged in co-marketing activities.

Import

Apart from obtaining an import license in accordance with the Licensing Regulation as mentioned above, pursuant to the Communiqué on Import of Certain Products that are Audited by the Ministry of Health (Communiqué No: 2012/20), a certificate of control shall be obtained from the Ministry of Health for the import of pharmaceutical products (and active substances).

This certificate of control shall be obtained before the import of the relevant pharmaceutical product by submitting certain documents such as a pro forma invoice or standard invoice, certificate of analysis, and approved health certificate issued by the competent authority in the country of origin. The certificates of control shall be valid for a period of 12 months except for the certificates of control issued for the pharmaceutical substances subject to the Communiqué on Standardization of Foreign Trade in Relation to Import of Certain Substances which Require a Special Permit to be Obtained from the Ministry of Health (Communiqué No: 2011/4), which shall be valid for a period of 6 months.

Specifications of any elementary substances used for manufacturing pharmaceutical products

In addition to the above, pursuant to Article 5 of the Regulation on Pharmaceutical and Medicinal Products (published in the Official Gazette dated October 23, 2003 and numbered25268); specifications of any elementary substances used for manufacturing pharmaceutical products shall be declared by the manufacturer during the license application to be registered by the Ministry of Health.

These specifications shall not be low quality when compared to Turkish Pharmacopeia, European Pharmacopeia, British Pharmacopeia or United States Pharmacopeia specifications. These specifications shall be attached to the petition or pro forma invoices to be submitted as per the decision of the relevant import regime.

Pursuant to Article 5 of the Pharmaceuticals Import Regulation, the specifications of the pharmaceutical products to be imported are specifications which are registered at the country of origin as the basis of the license thereof. The Ministry of Health shall approve these specifications. For the import of elementary substances of pharmaceuticals, according to Article 6 of the Pharmaceuticals Import Regulation, a certificate indicating that the substances have been manufactured in compliance with the appropriate specifications to be issued by the importer country's health authority is required to be submitted. Once the import is conducted, the Ministry of Health may also require a certificate of analysis of the manufacturer for each batch. Upon evaluation of the foregoing, the Ministry of Health issues a quality control certificate.

Timeline for registration

Licensing Regulation Article 15 regulates that, upon completion of the preliminary evaluation period which can be a maximum of 90 days (including the time period granted to the applicant to complete the missing documents/information in the application file); the applications shall be evaluated and concluded within 210 days.

However, the applications pertaining to pharmaceutical products which are original in treatment or diagnosis, which are innovative or are required from a public health perspective to reduce public healthcare expenditures and to ensure rapid public access to the drug, shall be completed within a maximum of 180 days.

Applicant

Where a pharmaceutical product will be imported, a certificate (and a Turkish translation thereof) issued by the licensor or the supplier demonstrating that the importer is the sole representative which is authorized to manufacture and/or sell the product in Turkey, or if any, a certificate illustrating that a real person or legal entity other than the sole authorized representative in Turkey has also been authorized for co-marketing, and the written consents of the real persons or legal entities which will be engaged in co-marketing activities.

Special protection for NCEs and innovative products

Although Turkey is not a member of the European Union, legislation in Turkey (and particularly the legislation regulating the Turkish pharmaceutical sector) follows the developments in European legislation. Therefore, following the EC Directive (2004/27/EC) ("EC Directive"), the Licensing Regulation was also amended by a regulation dated June 11, 2005.

The Turkish legislation did not establish a data exclusivity period in the same duration as regulated by the European legislation. According to this sub-paragraph of the Regulation, the original pharmaceutical products which have been licensed in a Customs Union Member State are subject to a data exclusivity period of six years. This term of six years starts from the "first" licensing of such original product in any of the member States to the Customs Union. Please note that the Licensing Regulation does not provide any further term of exclusivity in the event of new therapeutic indications, a case that is covered by the EC Directive.

On the other hand, communications with the legal department of the Ministry of Health reveals that the Turkish regulator is in fact aware of the amendment to Article 10 of the EC Directive as follows: "The ten-year period referred to in the second subparagraph shall be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies." and is actually tending towards allowing one year of additional protection for data exclusivity in the case of new therapeutic indications.

Data exclusivity issues

Turkey implemented patent protection to its regulatory system in 1995 and subscribed to apply the data exclusivity with TRIPS and Customs Union agreements. The legal ground of the data exclusivity provisions in Turkish Law is European Union Regulations.

On the other hand, there is no particular provision in Turkish Law which exposes the scope of the data exclusivity protection. Data exclusivity protection is only mentioned within Article 9(a) of the Licensing Regulation. Article 9 of the Regulation promulgates the procedure for an "Abbreviated Application."

As per Article 9(a), if the applicant is conducting his application through an abbreviated application, he shall not be required to provide the results of pre-clinical tests or clinical trials if it meets the following conditions set below:

  1. The medicinal product subject to the application is similar in principle to a medicinal product which has been licensed in Turkey previously and the permission is taken from the marketing authorization holder of the original medicinal product.
  2. The components of the medicinal product have reasonable activity and admissible reliability settled in medical utilization.
  3. The medicinal product is licensed as per the legislation in force and has elapsed from the data exclusivity period of the medicinal product. In order to apply this sub-provision, the original products should fall into one of the below product categories:

a. Products shall be original products that have been granted a license for the first time after January 1, 2001 in one of the countries of the Customs Union Area and for which no generic registration application had been filed in Turkey until January 1, 2005.

b. Original products that have been granted license for the first time after January 1, 2005 in one of the countries of the Customs Union Area.

Market exclusivity and generic pharmaceuticals

In European Union Regulations, market exclusivity is regulated as a different and separate protection period for two years during which a new drug is protected from direct competition from generics in a market. Please be informed that in Turkish Law there is no explicit provision for market exclusivity.

On the other hand it would not be false to state that the Ministry of Health's interpretation of the data exclusivity protection equals to only market exclusivity. In fact, we have experienced that Ministry of Health's practice of data exclusivity is to allow abbreviated license applications referring to an original product which is within the data exclusivity protection period and then to withhold the sales permission until the end of the data exclusivity period of the original product.

Evaluation of pricing and reimbursement for an NCE or an innovative product in Turkey

The pharmaceutical pricing system in Turkey is under the control of the Ministry of Health. Pursuant to the Communiqué amending the Communiqué concerning the Tariff to be Applied to Pricing of Pharmaceuticals ("Tariff Communiqué" dated April 14, 2012 and numbered 28264) the Ministry of Health exerts strict control over the pricing in the pharmaceutical sector by determining the innovator's base price on the first product to enter the market (i.e. original product). Subsequent generic entrants to the market must price their product at a predetermined percentage of the original product (i.e. generic product). In that respect, the Ministry of Health applies a reference pricing system to determine the prices of original and generic products.

Please note that a Price Evaluation Commission is formed with the participation of the representatives from the Ministry of Health, Ministry of Finance, State Planning Organization, Undersecretariat of Treasury and Directorate of Social Security Authority. The Price Evaluation Commission shall evaluate whether the reference prices should be raised, reduced or maintained. Such Commission also determines the periodical foreign currency band which is the basis of the reference prices. Such foreign currency band is currently between the lowest periodical Euro rate (lower limit) and the lowest periodical Euro rate plus 10% (upper limit).

A change in foreign currency rates up to 5% less than the lower limit and 5% more than the upper limit shall not affect the prices. However, if the change in the 90 day moving average of the foreign currency rate exceeds the abovementioned 5% limits, the Price Evaluation Commission may amend the prices.

The price of the original products without generics shall not exceed the reference price until the generics are placed on the market. The price of the original product with a generic product that has been licensed and placed on the market shall not exceed 60% of the base price registered under the Ministry of Health database.

The method of evaluating when to substitute prescribed pharmaceuticals with non-prescribed products is determined by protocols assigned by SSI, Ministry of Finance and Turkish Pharmacists Association. On the other hand, as mentioned by the Turkish Competition Authority in the April 20, 2009 dated decision for Sanofi Aventis; the current practice in the market is for pharmacists to provide pharmaceutically equivalent generic products instead of the prescribed product. As a matter of fact, it is an established practice for the pharmacists to direct customers to the lower priced equivalent generic product by indicating that they have the option to pay the extra price from the reference price determined by the Ministry of Health for the original product or buy the generic product which is within the reference price determined. There are two legal bases for such application, first of all it is accepted that the generic product is the exact subsidiary of the original product and secondly, it is the practice of SSI and Ministry of Finance which together holds approximately 80% of the pharmaceutical purchase in the Turkish market.

Comparison of Turkish and EU prices

Tariff Communiqué Article 2/h stipulated that prices of pharmaceuticals are determined based on the reference prices in 5 to 10 reference countries (among European Union countries) determined by the Ministry of Health. The reference price refers to the lowest warehouse sales price of the original and licensed product (exclusive of discount) in the reference countries. However, in case the country where the product is produced or imported from is not one of the reference countries but the warehouse sales price of the relevant product is lower than the reference prices in the reference countries, then the lower price shall be considered as the reference price.

Timeframe for price/reimbursement approval

According to Communiqué concerning the Tariff to be Applied to Pricing of the Pharmaceuticals (dated June 30, 2007 and numbered 26568) Article 4, the license holders shall apply to the Ministry of Health along with the Price Declaration Form as well as other documentation, which may be required depending on whether the product subject to price application is an original or a generic product. The applications to obtain an initial price shall be concluded within 60 days. Applications other than for the purposes of obtaining an initial price shall be concluded within 10 days.

Available reimbursements

With the radical change brought by the Code of Social Security Institution (dated May 16, 2006 and numbered 5502) which combined all social security institutions under the roof of the Social Security Institution (SSI), a list was published to indicate the pharmaceutical products to be reimbursed.

The list contains molecules against all kinds of diseases. Any product that is not included in the list will not be subject to reimbursement. On the other hand, the list is updated frequently (the latest update on August 22, 2012 being the 79th) and in this regard has been rapidly expanded since its first practice in 2005. New products entering into the market for the first time can be subjected to reimbursement upon approval of the Reimbursement Committee, which gathers at least quarterly to discuss and update the list indicating the molecules to be reimbursed. The Reimbursement Committee consists of doctors, pharmacists, public health experts, economists, statisticians, specialists, pharmacologists and biostatisticians who evaluate applications for reimbursement and amend the list of pharmaceuticals to be reimbursed according to the Directive on the Procedure and Principles of Practice of the Reimbursement Committee ("Directive on Reimbursement Committee").

The Communiqué on Health Implementations published by the SSI provides that the basic discount to be applicable to generic and original products shall be at a rate of 11%. As per the amendments to the relevant Communiqué on April 4, 2012, the following additional discount rates shall apply:

  1. 29% until reference price is determined (a total of 40%) and 17% after the reference price is determined (a total of 28%) for products which have been released to the market before August 1, 1987 (twenty year products) and have a warehouse sale price of 6.79 TL and above.
  2. 30% for original products of which generics have not been launched to the market (a total of 41%).
  3. 17% for original products of which generics have been launched to the market (a total of 28%).
  4. 17% for generic products (a total of 28%).

The abovementioned Communiqué also stipulates the terms of reimbursement for pharmaceutical products. Accordingly, in order for a listed pharmaceutical product to be reimbursed, first the discounted price thereof shall be calculated. Following such calculation, the equivalents of such pharmaceutical product shall be determined. Pursuant to Article 6.4.2 of the relevant Communiqué, a reimbursement price band is applicable which is between the lowest price in the determined equivalent pharmaceuticals group and 10% more than the lowest price in the determined equivalent pharmaceuticals group. However, we have been verbally informed by the officials in the Ministry of Health that for the pharmaceutical products placed on the market which have already been reimbursed based on a different reimbursement band before the introduction of the current reimbursement band, the products will continue to be reimbursed based on the original band.

Until December 3, 2010 the practice of the Ministry of Health was the base for evaluation of which products should be considered as original, generic, or twenty-years-old (introduced into the world market for the first time before 1/8/1987). After December 2010, the Turkish Drug and Medical Device Institution is the authority to evaluate any amendments to groups of products.

Availability and justification for premium prices

Pursuant to Article 6.4.1(10) of the Communiqué on Health Implementations, the provisions for lowest reference pricing and price ratio shall not be applied to non-prescribed products and/or products that are not within the list of products to be reimbursed. These products will be evaluated without differentiating whether they are original, twenty year, co-marketing or generic. Regardless, the price shall not be higher than the official highest warehouse sales price in the reference countries.

According to Tariff Communiqué Article 5/a, even if there is a price determined by the Turkish Drug and Medical Device Institution, reevaluation of the price may be conducted for products which may not be possible to import due to economic reasons and therefore threaten public finance and health, on the condition that it is proven with documents and determined by the Price Evaluation Committee. In such case, the price of the product may be determined up to 15% higher than the price of the lowest reference price. If there is any other product used for the same indications, then the price of the closest option shall be the reference point. Even if the price gap between the product to be reevaluated and the product with the same indications is high, the new warehouse sales price determined based on the cost sheet approved by the certified public accountant shall not exceed 200% of the prior warehouse sales price.

Regulation of the generic price level

Subsequent generic entrants to the market must price their product at a predetermined percentage of the original product (i.e. generic product). In that respect, the Ministry of Health applies a reference pricing system to determine the prices of original and generic products.

In this regard, according to Article 4/1 (a) of the Tariff Communiqué the warehouse sales price of generic products without the original products released in the Turkish market can be up to 60% of the reference price registered to the Ministry of Health. Starting with the first generic product, all generic products may be priced on 60% of the original product reference price.

Market observations

In general, most foreign investors prefer acquiring an existing and active Turkish company for their prospective activities in the pharma market; rather than establishing a brand new company. This is especially due to the Ministry of Health's practice towards the Turkish pharmaceutical market both in sales and marketing and the regulatory aspects, which results in foreign investors entering the Turkish market via acquisition of an already existing and well-established company. Some recent acquisitions are:

  • Acquisition of Dr. F. Frik by Yeni Recordati (with an EBITDA of 14)
  • Acquisition of Biofarma İlaç by Biofarm
  • Acquisition of Birgi by Mefar
  • Acquisition of Mustafa Nevzat by Amgen
  • Acquisiton of Yeni İlaç by Recordati SL. (seller side representation)

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Dr. E. Seyfi Moroğlu, LL.M.
Similar Articles
Relevancy Powered by MondaqAI
Celen Law Office
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Celen Law Office
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions